| Previous Close | 4.27 |
| Open | 4.34 |
| Volume | 91,594 |
| Avg. Volume (3M) | 241,291 |
| Market Cap | 1,583,777,280 |
| Price / Earnings (Forward) | 59.88 |
| Price / Sales | 2.00 |
| Price / Book | 1.60 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2024 |
| Profit Margin | -22.05% |
| Operating Margin (TTM) | -17.68% |
| Diluted EPS (TTM) | -0.500 |
| Quarterly Revenue Growth (YOY) | -5.80% |
| Total Debt/Equity (MRQ) | 48.54% |
| Current Ratio (MRQ) | 2.09 |
| Operating Cash Flow (TTM) | -36.05 M |
| Levered Free Cash Flow (TTM) | -188.42 M |
| Return on Assets (TTM) | -1.77% |
| Return on Equity (TTM) | -16.25% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Mixed | |
| Stock | Evotec SE | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | -0.5 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | -0.75 |
|
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Core |
| % Held by Institutions | 2.37% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Dcf Advisers, Llc | 30 Sep 2024 | 217,055 |
| Mediolanum International Funds Ltd | 30 Sep 2024 | 140,383 |
| Clear Harbor Asset Management, Llc | 30 Sep 2024 | 28,600 |
| Briaud Financial Planning, Inc | 30 Sep 2024 | 2,160 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 8.00 (HC Wainwright & Co., 79.37%) | Buy |
| Median | 5.90 (32.29%) | |
| Low | 3.80 (Jefferies, -14.80%) | Hold |
| Average | 5.90 (32.29%) | |
| Total | 1 Buy, 1 Hold | |
| Avg. Price @ Call | 3.80 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 07 Nov 2024 | 8.00 (79.37%) | Buy | 4.25 |
| Jefferies | 07 Oct 2024 | 3.80 (-14.80%) | Hold | 3.34 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |